Latest & greatest articles for preeclampsia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on preeclampsia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on preeclampsia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for preeclampsia

21. A study of the diagnostic value of Inhibin A Tests for occurrence of preeclampsia in pregnant women Full Text available with Trip Pro

A study of the diagnostic value of Inhibin A Tests for occurrence of preeclampsia in pregnant women Hypertensive disorders are common during pregnancy, and are among 3 important causes of maternal death. Preeclampsia occurs in 3 to 5% of pregnancies. Early diagnosis of this disorder can lead to better pregnancy outcomes.The aim of this study was to determine the relationship between inhibin A serum levels during second stage pregnancy screening tests, and incidence and severity (...) version 18 and independent t-test, ANOVA and descriptive statistics were used. P-values less than 0.05 were considered significant.Among the 300 pregnant women who were studied, the gestational age at the time of acquiring blood samples was as follows: 169 cases (56.3%) at 16-17 weeks, 77 cases (25.7%) at 18-19 weeks and 14 cases at 20 weeks (4.7%). In this study, MOM of inhibin A was more than 1.25 in 12 cases that finally, preeclampsia occurred in them. This relationship was statistically

2018 Electronic physician

22. Maternal and child health: Associations between the timing and dosing of aspirin prophylaxis and term and preterm pre-eclampsia

between the timing and dosing of aspirin prophylaxis and term and preterm pre-eclampsia Lisa Askie 1 , Lelia Duley 2 Statistics from Altmetric.com Commentary on: Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of pretermand term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2018;218:287–93. Context Aspirin prophylaxis during pregnancy has been estimated in a participant-level meta-analysis to reduce the risk of pre-eclampsia by 10%. 1 Evidence-based guidelines (...) Maternal and child health: Associations between the timing and dosing of aspirin prophylaxis and term and preterm pre-eclampsia Associations between the timing and dosing of aspirin prophylaxis and term and preterm pre-eclampsia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username

2018 Evidence-Based Medicine

23. Aspirin versus placebo in pregnancies at high risk for preterm pre-eclampsia. Full Text available with Trip Pro

Aspirin versus placebo in pregnancies at high risk for preterm pre-eclampsia. A recent multicentre placebo-controlled trial by Rolnick et al. has indicated that taking 150 mg aspirin daily in women at high risk of pre-eclampsia reduced the incidence of the disease from 4.3% to 1.5% in comparison with placebo. Although the findings of this study are important, a high proportion of women withdrew their consent and not all safety outcomes have been reported. This journal watch article discusses

2018 Obstetric medicine Controlled trial quality: uncertain

24. Pre-eclampsia

Pre-eclampsia Pre-eclampsia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Pre-eclampsia Last reviewed: February 2019 Last updated: August 2018 Summary Hypertensive syndrome that occurs in pregnant women after 20 weeks' gestation, consisting of new-onset, persistent hypertension with either proteinuria or evidence of systemic involvement. All pregnant women presenting with hypertension and either proteinuria (...) or evidence of systemic involvement require close assessment and monitoring for pre-eclampsia and its complications. Delivery is the definitive treatment; the decision about when and how to deliver should only be made after a thorough assessment of the risk and benefits to the mother and baby. Other mainstays of management include antihypertensive therapy, seizure control, and fluid restriction. Maternal mortality is highest after delivery, so vigilance should be maintained in the postpartum period. Can

2018 BMJ Best Practice

25. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history Full Text available with Trip Pro

Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history The Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidence-Based Preeclampsia Prevention trial demonstrated that in women who were at high risk for preterm preeclampsia with delivery at <37 weeks' gestation identified by screening by means of an algorithm (...) that combines maternal factors and biomarkers at 11-13 weeks' gestation, aspirin administration from 11 to 14 until 36 weeks' gestation was associated with a significant reduction in the incidence of preterm preeclampsia (odds ratio 0.38; 95% confidence interval, 0.20 to 0.74; P=0.004).We sought to examine whether there are differences in the effect of aspirin on the incidence of preterm preeclampsia in the Aspirin for Evidence-Based Preeclampsia Prevention trial in subgroups defined according to maternal

2018 EvidenceUpdates

26. Epidural therapy for the treatment of severe pre-eclampsia in non labouring women. Full Text available with Trip Pro

Epidural therapy for the treatment of severe pre-eclampsia in non labouring women. Pre-eclampsia is a pregnancy-specific multi-organ disorder, which is characterised by hypertension and multisystem organ involvement and which has significant maternal and fetal morbidity and mortality. Failure of the placental vascular remodelling and reduced uteroplacental flow form the etiopathological basis of pre-eclampsia. There are several established therapies for pre-eclampsia including antihypertensives (...) and anticonvulsants. Most of these therapies aim at controlling the blood pressure or preventing complications of elevated blood pressure, or both. Epidural therapy aims at blocking the vasomotor tone of the arteries, thereby increasing uteroplacental blood flow. This review was aimed at evaluating the available evidence about the possible benefits and risks of epidural therapy in the management of severe pre-eclampsia, to define the current evidence level of this therapy, and to determine what (if any) further

2017 Cochrane

27. Planned caesarean section versus planned vaginal birth for severe pre-eclampsia. Full Text available with Trip Pro

Planned caesarean section versus planned vaginal birth for severe pre-eclampsia. Pre-eclampsia is a very frequent complication of pregnancy, and anticipation of birth is often necessary. However, the best mode of giving birth remains to be established, although observational studies suggest better maternal and perinatal outcomes with vaginal birth.To assess the effects of a policy of planned caesarean section versus planned vaginal birth for women with severe pre-eclampsia on mortality (...) and morbidity for mother and baby.We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (6 September 2017) and reference lists of retrieved studies.We planned to include all randomised trials of planned caesarean section versus planned vaginal birth for pregnant women with severe pre-eclampsia. Quasi-randomised and non-randomised studies are not eligible for inclusion in this review.The

2017 Cochrane

28. Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin Full Text available with Trip Pro

Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin To examine whether the reduced incidence of preeclampsia in non-diabetic obese pregnant women treated with metformin is mediated by changes in insulin resistance.This was a secondary analysis of obese pregnant women in a randomised trial (MOP trial). Fasting plasma glucose and insulin were measured in 384 of the 400 women who participated in the MOP trial. Homeostasis model assessment (...) of insulin resistance (HOMA-IR) was compared in the metformin and placebo groups and in those that developed preeclampsia versus those that did not develop preeclampsia.At 28 weeks, median HOMA-IR was significantly lower in the metformin group. Logistic regression analysis demonstrated that there was a significant contribution in the prediction of preeclampsia from maternal history of chronic hypertension and gestational weight gain, but not HOMA-IR either at randomisation (p = 0.514) or at 28 weeks (p

2017 Obstetric medicine Controlled trial quality: uncertain

29. MicroRNAs: New Players in the Pathobiology of Preeclampsia Full Text available with Trip Pro

MicroRNAs: New Players in the Pathobiology of Preeclampsia Our understanding of how microRNAs (miRNAs) regulate gene networks and affect different molecular pathways leading to various human pathologies has significantly improved over the years. In contrary, the role of miRNAs in pregnancy-related hypertensive disorders such as preeclampsia (PE) is only beginning to emerge. Recent papers highlight that adverse pregnancy outcomes are associated with aberrant expression of several miRNAs

2017 Frontiers in cardiovascular medicine

30. The Impact of Silymarin on Improvement of Hepatic Abnormalities in Patients with Severe Preeclampsia: A Randomized Clinical Trial Full Text available with Trip Pro

The Impact of Silymarin on Improvement of Hepatic Abnormalities in Patients with Severe Preeclampsia: A Randomized Clinical Trial Preeclampsia is a pregnancy-specific disorder, associated with increased blood pressure and proteinuria, and in extreme cases it can also cause liver and kidney problems.To determine the impact of silymarin on the improvement of severe preeclampsia.This randomized clinical trial was conducted at Hajar Hospital in Shahrekord, Iran, from April 2014 to September 2015 (...) . Sixty patients whose pregnancy had ended as a result of severe preeclampsia, were entered into the study. Patients were randomly divided into two groups of thirty study and control groups. In addition to current treatment for preeclampsia, case groups were administered 70 mg of silymarin, three and twenty four hours after the termination of pregnancy. The control group received placebo at the same time. The blood pressure and AST, ALT, ALP, LDH, uric acid, bilirubin and kidney tests were compared

2017 Electronic physician Controlled trial quality: uncertain

31. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. Full Text available with Trip Pro

Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. Preterm preeclampsia is an important cause of maternal and perinatal death and complications. It is uncertain whether the intake of low-dose aspirin during pregnancy reduces the risk of preterm preeclampsia.In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1776 women with singleton pregnancies who were at high risk for preterm preeclampsia to receive aspirin, at a dose of 150 mg per day (...) , or placebo from 11 to 14 weeks of gestation until 36 weeks of gestation. The primary outcome was delivery with preeclampsia before 37 weeks of gestation. The analysis was performed according to the intention-to-treat principle.A total of 152 women withdrew consent during the trial, and 4 were lost to follow up, which left 798 participants in the aspirin group and 822 in the placebo group. Preterm preeclampsia occurred in 13 participants (1.6%) in the aspirin group, as compared with 35 (4.3

2017 NEJM Controlled trial quality: predicted high

32. Frontal lobe meningioma mimicking preeclampsia: A case study Full Text available with Trip Pro

Frontal lobe meningioma mimicking preeclampsia: A case study We report a case of a left frontal lobe meningioma presenting in a woman with proteinuric preeclampsia in her first term pregnancy. The patient had a background of antepartum migraines that resolved in the second trimester of pregnancy. Postpartum, she required urgent surgery and sustained convulsions after surgery. She had no residual disease and has had another successful pregnancy. This case highlights the importance of cerebral (...) imaging in the context of an atypical clinical course of preeclampsia. Although headaches are common in pregnancy and usually benign, other, more serious, diagnoses should be considered with atypical headaches, a change in the nature of the headache, and headaches that persist despite appropriate treatment. A full neurological examination including fundoscopy to exclude papilloedema should be performed and abnormal findings require further investigation.

2017 Obstetric medicine

33. Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. (Abstract)

Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement. Preeclampsia affects approximately 4% of pregnancies in the United States. It is the second leading cause of maternal mortality worldwide and may lead to serious maternal complications, including stroke, eclampsia, and organ failure. Adverse perinatal outcomes for the fetus and newborn include intrauterine growth restriction, low birth weight, and stillbirth. Many of the complications associated (...) with preeclampsia lead to early induction of labor or cesarean delivery and subsequent preterm birth.Preeclampsia is more prevalent among African American women than among white women. Differences in prevalence may be, in part, due to African American women being disproportionally affected by risk factors for preeclampsia. African American women also have case fatality rates related to preeclampsia 3 times higher than rates among white women. Inequalities in access to adequate prenatal care may contribute

2017 JAMA

34. Final recommendation statement: preeclampsia: screening.

of Risk All pregnant women are at risk for preeclampsia and should be screened. Important clinical conditions associated with increased risk for preeclampsia include a history of eclampsia or preeclampsia (particularly early-onset preeclampsia), a previous adverse pregnancy outcome, maternal comorbid conditions (including type 1 or 2 diabetes prior to pregnancy, gestational diabetes, chronic hypertension, renal disease, and autoimmune diseases), and multifetal gestation. Other risk factors include (...) mortality, morbidity from eclampsia, HELLP (hemolysis, elevated liver enzyme levels, low platelet counts) syndrome, organ damage or failure, fetal growth restriction, preterm delivery, low birth weight, stillbirth, and placental abruption. Evidence was sought on the screening test performance of clinical blood pressure measurement, urinalysis, or both for identifying women with preeclampsia at the time of screening (KQ4), to compare the effectiveness of different screening protocols (e.g., instruments

2017 National Guideline Clearinghouse (partial archive)

35. Advocacy is essential to supporting women with pre-eclampsia Full Text available with Trip Pro

Advocacy is essential to supporting women with pre-eclampsia Advocacy has a critical role in advancing the maternal health agenda. Patient advocacy groups can hold governments and other stakeholders accountable and ensure that commitments are translated into concrete action. This article highlights the advocacy efforts of the Preeclampsia Foundation, a patient advocacy organisation that aims to improve the diagnosis, management, and prevention of pre-eclampsia through research and improved

2017 Obstetric medicine

36. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis

Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid (...) to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis Frampton G K, Jones J, Rose M & Payne L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Frampton G K, Jones J, Rose M & Payne L. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women

2017 Health Technology Assessment (HTA) Database.

37. Preeclampsia: Screening

. Myatt L, Roberts JM. Preeclampsia: syndrome or disease? Curr Hypertens Rep . 2015;17(11):83. 3. Redman C. Pre-eclampsia: a complex and variable disease. Pregnancy Hypertens . 2014;4(3):241-2. 4. Henderson JT, Thompson JH, Burda BU, Cantor A, Beil T, Whitlock EP. Screening for Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 148. AHRQ Publication No. 14-05211-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2017. 5 (...) . 2005;111(5):697-716. 16. Meads CA, Cnossen JS, Meher S, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess . 2008;12(6):iii-iv, 1-270. 17. Siddique J, Lantos JD, VanderWeele TJ, Lauderdale DS. Screening tests during prenatal care: does practice follow the evidence? Matern Child Health J . 2012;16(1):51-9. 18. U.S. Preventive Services Task Force. Screening for preeclampsia. In: Guide

2017 U.S. Preventive Services Task Force

38. The Relationship Between Blood Lead Level and Preeclampsia Full Text available with Trip Pro

The Relationship Between Blood Lead Level and Preeclampsia Lead is a heavy metal to which people are commonly exposed. One of the possible mechanisms of tissue damages caused by this toxic metal is oxidative stress, which in turn may cause numerous pregnancy complications such as preeclampsia. The present study was conducted to determine the relationship between maternal Blood Lead Level (BLL) and preeclampsia.The present case-control study was conducted on 158 pregnant women admitted (...) in the control group and 8.04±3.4 μg/dl in the preeclampsia group. The two groups were matching in terms of the mother's age and education and the household income. A significant relationship was observed between BLL and preeclampsia (p=0.028), as per every unit of increase (1 μg/dl) in BLL, systolic blood pressure increased by 0.014 mm Hg and diastolic blood pressure by 0.013 mm Hg (p=0.004).The results obtained suggest a relationship between BLL and preeclampsia. Global health measures should be taken

2016 Electronic physician

39. The evaluation of serum homocysteine, folic acid, and vitamin B12 in patients complicated with preeclampsia Full Text available with Trip Pro

The evaluation of serum homocysteine, folic acid, and vitamin B12 in patients complicated with preeclampsia Increased plasma homocysteine may be associated with adverse pregnancy outcomes, such as preeclampsia. The aim of this study was to determine the plasma homocysteine, serum folate, and vitamin B12 levels in preeclamptic pregnant women.This case-control study was conducted in 2016 in Ahwaz on 51 pregnant women with preeclampsia and 51 healthy pregnant women of the same gestational age, who (...) served as controls. The case group also was subdivided into severe and non-severe preeclampsia. Patients' data were collected through a questionnaire and medical records. Serum homocysteine, folic acid, and vitamin B12 were analyzed using chemiluminescent assay. The results were compared between two groups. Statistical analyses were done using IBM-SPSS 20.0. A Kolmogorov-Smirnov test, independent samples t-test, Mann-Whitney test, and Chi-square test were used for data analysis.No different

2016 Electronic physician

40. The impact of an educational pamphlet on knowledge and anxiety in women with preeclampsia. Full Text available with Trip Pro

to an intervention group (who received a pamphlet) or a control group (who did not received a pamphlet). The pamphlet and questionnaire, both designed by a multidisciplinary team, were read and answered at the same time.Baseline and demographic characteristics were similar between the two groups. Knowledge about the symptoms of pre-eclampsia was excellent in both groups (61% to 100% correct answers). Women in both groups were well aware that preeclampsia in the past (P = 0.22) and a family history (...) The impact of an educational pamphlet on knowledge and anxiety in women with preeclampsia. This study was undertaken to evaluate whether or not an educational pamphlet could improve knowledge without increasing anxiety in women with preeclampsia.One hundred women recruited from an inpatient setting with suspected or proven preeclampsia were asked to answer a questionnaire assessing demographics, knowledge (primary outcome), anxiety and satisfaction (secondary outcomes) after being randomized

2016 Obstetric medicine Controlled trial quality: uncertain